we are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.
Company profile
Ticker
HOWL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
823523180
HOWL stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Other Events
9 Feb 24
424B5
Prospectus supplement for primary offering
9 Feb 24
8-K
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
8 Jan 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
Latest ownership filings
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G
BANK OF AMERICA CORP /DE/
13 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
4
Michael B. Atkins
4 Jan 24
3
Michael B. Atkins
4 Jan 24
4
Timothy W. Trost
4 Jan 24
4
Ellen Lubman
4 Jan 24
4
Randi Isaacs
4 Jan 24
4
Chulani Karunatilake
4 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 151.29 mm | 151.29 mm | 151.29 mm | 151.29 mm | 151.29 mm | 151.29 mm |
Cash burn (monthly) | 2.46 mm | (no burn) | 3.08 mm | 3.39 mm | 2.40 mm | 3.32 mm |
Cash used (since last report) | 16.43 mm | n/a | 20.58 mm | 22.64 mm | 16.03 mm | 22.18 mm |
Cash remaining | 134.85 mm | n/a | 130.71 mm | 128.65 mm | 135.26 mm | 129.10 mm |
Runway (months of cash) | 54.8 | n/a | 42.4 | 37.9 | 56.3 | 38.8 |
Institutional ownership, Q3 2023
78.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 39 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 10 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 50.95 bn |
Total shares | 33.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 6.14 mm | $13.15 bn |
MPM Asset Management | 4.28 mm | $9.17 bn |
MPM BioVentures 2014 | 3.21 mm | $51.53 mm |
Partner Fund Management | 2.56 mm | $5.47 bn |
MPM Oncology Impact Management | 2.39 mm | $5.11 bn |
Taiho Ventures | 2.07 mm | $33.17 mm |
Arkin Moshe | 2.05 mm | $0.00 |
Rubric Capital Management | 1.94 mm | $4.14 bn |
Longwood Fund III GP | 1.68 mm | $26.88 mm |
BAC Bank Of America | 1.53 mm | $3.28 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Jan 24 | Michael B. Atkins | Stock Option Common Stock | Grant | Acquire A | No | No | 5.25 | 35,000 | 183.75 k | 35,000 |
2 Jan 24 | Daniel J Hicklin | Stock Option Common Stock | Grant | Acquire A | No | No | 4.64 | 435,000 | 2.02 mm | 435,000 |
2 Jan 24 | Chulani Karunatilake | Stock Option Common Stock | Grant | Acquire A | No | No | 4.64 | 150,000 | 696.00 k | 150,000 |
2 Jan 24 | Randi Isaacs | Stock Option Common Stock | Grant | Acquire A | No | No | 4.64 | 200,000 | 928.00 k | 200,000 |
News
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects Of Pro-Inflammatory Cytokine Therapeutics WTX-518 And WTX-712 At AACR 2024 Annual Meeting
5 Apr 24
JMP Securities Initiates Coverage On Werewolf Therapeutics with Market Outperform Rating, Announces Price Target of $12
3 Apr 24
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Maintains $15 Price Target
7 Mar 24
Recap: Werewolf Therapeutics Q4 Earnings
7 Mar 24
Werewolf Therapeutics Q4 EPS $(0.33) Beats $(0.43) Estimate, Sales $1.50M Miss $1.94M Estimate
7 Mar 24
Press releases
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
5 Apr 24
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
4 Apr 24
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24